RTW Biotech Opportunities Ltd, a London-listed investment trust focused on the biotechnology sector, has reported a net asset value (NAV) of $2.61 per share for the month of May 2025. The figure, released in a regulatory update, represents a slight increase from the previous month's NAV, reflecting a modest recovery in biotech valuations after a turbulent spring.
The trust, which holds a diversified portfolio of both private and publicly traded biotech firms across the US and Europe, has seen its NAV fluctuate in line with broader market sentiment towards risk assets. May's performance was supported by positive clinical data readouts from a handful of portfolio companies, though wider macroeconomic headwinds — including persistent inflation and uncertainty over US interest rate policy — continued to weigh on the sector.
Analysts note that biotech investment trusts often trade at a discount or premium to NAV depending on investor sentiment. RTW Biotech Opportunities has historically commanded a premium due to its specialist focus and active management approach. However, the sector has faced a prolonged downturn since 2021, with rising interest rates reducing the present value of future drug revenues and making speculative biotech stocks less attractive.
For UK investors and pension holders, the performance of trusts like RTW Biotech Opportunities offers a window into the health of the innovation-driven healthcare market. While the sector carries higher risk than broader equity indices, it also provides potential for outsized returns if new therapies gain regulatory approval. The trust's May NAV suggests a stabilisation, but not yet a decisive recovery.
Source: RTW Biotech Opportunities Ltd regulatory announcement